Skip to main content

Table 3 Acute toxicities of N group and CRT group

From: Comparison of radiotherapy combined with nimotuzumab vs. chemoradiotherapy for locally recurrent nasopharyngeal carcinoma

Toxicities

N group

CRT group

P

Leukopenia

  

<  0.001

 G0

25 (78.1%)

16 (29.1%)

 

 G1

7 (21.9%)

17 (30.9%)

 

 G2

0 (0.0%)

14 (25.5%)

 

 G3

0 (0.0%)

6 (10.9%)

 

 G4

0 (0.0%)

2 (3.6%)

 

Neutropenia

  

<  0.001

 G0

30 (93.7%)

22 (40.0%)

 

 G1

2 (6.3%)

14 (25.5%)

 

 G2

0 (0.0%)

12 (21.8%)

 

 G3

0 (0.0%)

5 (9.1%)

 

 G4

0 (0.0%)

2 (3.6%)

 

Anemia

  

0.085

 G0

29 (90.7%)

37 (67.3%)

 

 G1

1 (3.1%)

10 (18.2%)

 

 G2

1 (3.1%)

6 (10.9%)

 

 G3

1 (3.1%)

2 (3.6%)

 

Thrombocytopenia

  

0.082

 G0

31 (96.9%)

42 (76.4%)

 

 G1

1 (3.1%)

5 (9.1%)

 

 G2

0 (0.0%)

6 (10.9%)

 

 G3

0 (0.0%)

2 (3.6%)

 

Hepatoxicity

  

0.009

 G0

28 (87.5%)

30 (54.6%)

 

 G1

4 (12.5%)

13 (23.6%)

 

 G2

0 (0.0%)

11 (20.0%)

 

 G3

0 (0.0%)

1 (1.8%)

 

Weight Loss

  

0.047

 G0

29 (90.6%)

40 (72.7%)

 

 G1

3 (9.4%)

15 (27.3%)

 

Salivary glands injury

  

0.538

 G0

3 (9.4%)

2 (3.6%)

 

 G1

27 (84.3%)

49 (89.1%)

 

 G2

2 (6.3%)

4 (7.3%)

 

Dermatitis

  

0.005

 G0

12 (37.5%)

4 (7.3%)

 

 G1

17 (53.1%)

45 (81.8%)

 

 G2

3 (9.4%)

5 (9.1%)

 

 G3

0 (0.0%)

1 (1.8%)

 

Nausea

  

<  0.001

 G0

28 (87.5%)

21 (38.2%)

 

 G1

3 (9.4%)

29 (52.7%)

 

 G2

1 (3.1%)

5 (9.1%)

 

Vomiting

  

0.612

 G0

28 (87.5%)

45 (81.8%)

 

 G1

3 (9.4%)

4 (7.3%)

 

 G2

1 (3.1%)

5 (9.1%)

 

 G3

0 (0.0%)

1 (1.8%)

 

Mucositis oral

  

0.002

 G0

12 (37.5%)

3 (5.5%)

 

 G1

16 (50.0%)

40 (72.7%)

 

 G2

3 (9.4%)

10 (18.2%)

 

 G3

1 (3.1%)

2 (3.6%)